Additivity of molecular fields: CoMFA study on dual activators of PPARα and PPARγ

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 3015-3025

  Khanna, Smriti ^a   Sobhia, M E ^a   Bharatam, Prasad V ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; FARGLITAZAR; FENOFIBRATE; GW 409544; GW 6471; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BINDING AFFINITY; CANCER; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONCEPT FORMATION; DRUG ACTIVATION; ENZYME ACTIVATION; HYDROGEN BOND; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IC 50; INSULIN RESISTANCE; MALARIA; METHODOLOGY; MOLECULAR BIOLOGY; MOLECULAR DOCKING; MOLECULAR FIELD ANALYSIS; MOLECULAR MODEL; PHARMACOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATISTICAL ANALYSIS; VALIDATION PROCESS;

BENZOFURANS; BINDING SITES; DRUG DESIGN; LIGANDS; MODELS, MOLECULAR; OXADIAZOLES; OXAZINES; PPAR ALPHA; PPAR GAMMA; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 17444407063     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049383s     Document Type: Article

References (47)

1. Golas, J. M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J.; Frost, P.; Ye, P.; Boschelli, D. H.; Boschelli, F. SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, Is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice. Cancer Res. 2003, 63, 375-381.
2. Beck, M. T.; Chen, N. Y.; Franek, K. J.; Chen, W. Y. Prolactin Antagonist-endostatin Fusion Protein as a Targeted Dual-Functional Therapeutic Agent for Breast Cancer. Cancer Res. 2003, 63, 3598-3604.
3. 2-Adrenoceptor Agonists. J. Med. Chem. 2003, 46, 3210-3220.
4. Heppner, D. G.; Ballou, W. R. Malaria in 1998: advances in diagnosis, drugs and vaccine development. Curr. Opin. Infect. Dis. 1998, 519-530.
5. Rainov, N. G.; Heidecke, V. Long-term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J. Neurooncol. 2004, 66, 197-201.
6. Burgaud, J. L.; Riffaud, J. P.; Soldato, P. D. Nitric-Oxide Releasing Molecules: A New Class of Drugs with Several Major Indications. Curr. Pharm. Des. 2002, 8, 201-213.
7. Willson, T. M.; Brown, P. J.; Sternbach, D. D.; Henke, B. R. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527-541.
8. Sohda, T.; K., M.; Imamiya, E.; Sugiyama, Y.; Fujita, T.; Kawamatsu, Y. Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1- Methylcyclohexylmethoxybenzyl] thiazolidine-2,4-dione (ADD-3878) and Its Derivatives. Chem. Pharm Bull. 1982, 3580-3600.
9. Oberfield, J. L.; Collins, J. L.; Holmes, C. P.; Goreham, D. M.; Cooper, J. P.; Cobb, J. E.; Lenhard, J. M.; Hull-Ryde, E. A.; Mohr, C. P.; Blanchard, S. G.; Parks, D. J.; Moore, L. B.; Lehmann, J. M.; Plunket, K.; Miller, A. B.; Milburn, M. V.; Kliewer, S. A.; M., W. T. A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. 1999, 96, 6102-6106.
10. Dow, R. L.; Bechle, B. M.; Chou, T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-dines as Potent Hypoglycemic Agents. J. Med. Chem. 1991, 34, 1538-1554.
11. Momose, Y.; Maekawa, T.; Yamano, T.; Kawada, M.; Odaka, H.; Ikeda, H.; Sohda, T. Novel 5-Substituted 2,4-Thiazolidinedione and 2,4-Oxazolidinedione Derivatives as Insulin Sensitizers with Antidiabetic Activities. J. Med. Chem. 2002, 45, 1518-1534.
12. Shinkai, H.; Onogi, S.; Tanaka, M.; Shibata, T.; Iwao, M.; Wakitani, K.; Uchida, I. Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents. J. Med. Chem. 1998, 41, 1927-1933.
13. Momose, Y.; Maekawa, T.; Odaka, H.; Ikeda, H.; Yamano, T.; Sohda, T. Novel 5-Substituted-1H-tetrazole Derivatives as Potent Glucose and Lipid Lowering Agents. Chem. Pharm. Bull. 2002, 50, 100-111.
14. Henke, B. R.; Blanchard, S. G.; Brackeen, M. F.; Brown, K. K.; Cobb, J. E.; Collins, J. L.; Harrington, W. W. J.; Hashim, M. A.; Hull-Ryde, E. A.; Kaldor, I.; Kliewer, S. A.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J. M.; Lenhard, J. M.; Orband-Miller, L. A.; Miller, J. F.; Mook, R. A.; Noble, S. A.; Oliver, W. J.; Parks, D. J.; Plunket, K. D.; Szewczyk, J. R.; Willson, T. M. N-(2-Benzylphenyl)-L-tyrosine PPARγ Agonists. I. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents. J. Med. Chem. 1998, 41, 5020-5036.
15. Collins, J. L.; Blanchard, S. G.; Boswell, E. G.; Charifson, P. S.; Cobb, J. E.; Henke, B. R.; Hull-Ryde, E. A.; Kazmierski, W. W.; Lake, D. H.; Leesnitzer, L. M.; Lehmann, J.; Lenhard, J. M.; Orband-Miller, L. A.; Gray-Nunez, Y.; Parks, D. J.; Plunket, K. D.; Tong, W. N-(2-Benzoylphenyl)-L- tyrosine PPAR-γ Agonists. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety. J. Med. Chem. 1998, 41, 5037-5054.
16. Cobb, J. E.; Blanchard, S. G.; Boswell, E. G.; Brown, K. K.; Charifson, P. S.; Cooper, J. P.; Collins, J. L.; Dezube, M.; Henke, B. R.; Hull-Ryde, E. A.; Lake, D. H.; Lenhard, J. M.; Oliver, W. J.; Oplinger, J.; Pentti, M.; Parks, D. J.; Plunket, K. D.; Tong, W. N-(2-Benzoylphenyl)-L-tyrosine PPAR-γ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent. J. Med. Chem. 1998, 41, 5055-5069.
17. (a) Buckle, D. R.; Cantello, B. C. C.; Cawthorne, M. A.; Coyle, P. J.; Dean, D. K.; Faller, A.; Haigh, D.; Hindley, R. M.; Jefcott, L. J.; Lister, C. A.; Pinto, I. L.; Rami, H. K.; Smith, D. G.; Smith, S. A. Nonthiazolidinedione Antihyperglycemic Agents. 1: α-Heteroatom Substituted β- Phenylpropanoic Acids. Bioorg. Med. Chem. Lett. 1996, 6, 2121-2126.
18. (b) Buckle, D. R.; Cantello, B. C. C.; Cawthorne, M. A.; Coyle, P. J.; Dean, D. K.; Faller, A.; Haigh, D.; Hindley, R. M.; Jefcott, L. J.; Lister, C. A.; Pinto, I. L.; Rami, H. K.; Smith, D. G.; Smith, S. A. Nonthiazolidinedione Antihyperglycemic Agents. 2: α-Carbon Substituted β-Phenylpropanoic Acids. Bioorg. Med. Chem. Lett. 1996, 6, 2127-2130.
19. Henke, B. R. Proxisome Proliferator-Activated Receptor α/γ Dual Agonists for the Treatment of Type 2 Diabetes. J. Med. Chem. 2004, 47, 4118-4127.
20. Lohray, B. B.; Bhushan, V.; Bajji, A. C.; Kalchar, S.; Poondra, R. R.; Padakanti, S.; Chakrabarti, R.; Vikramadityan, R. K.; Mishra, P.; Juluri, S.; Mamidi, N. V. S. R.; Rajagopalan, R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl] -2-ethoxypropanoic Acid [(-)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Acitivity. J. Med. Chem. 1999, 42, 2569-2581.
21. Sauerberg, P.; Pettersson, I.; Jeppesen, L.; Bury, P. S.; Mogensen, J. P.; Wassermann, K.; Brand, C. L.; Sturis, J.; Woldike, H. F.; Fleckner, J.; Andersen, A. T.; Mortensen, S. B.; Svensson, L. A.; Rasmussen, H. B.; Lehmann, S. V.; Polivka, Z.; Sindelar, K.; Panajotova, V.; Ynddal, L.; Wulff, E. M. Novel Tricyclic-α-alkoxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity. J. Med. Chem. 2002, 45, 789-804.
22. Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H. Design, Synthesis and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Human Peroxisome Proliferator Activated Receptor Activators. Discovery of Potent and Human Peroxisome Proliferator Activated Receptor α Subtype-Selective Activators. J. Med. Chem. 2003, 46, 3581-3599.
23. Ebdrup, S.; Pettersson, I.; Rasmussen, H. B.; Deussen, H.; Jensen, A. F.; Mortensen, S. B.; Fleckner, J.; Pridal, L.; Nygaard, L.; Sauerberg, P. Synthesis and Biological and Structural Characterization of the Dual-Acting Peroxisome Proliferator-Activated Receptor α/γ Agonist Ragaglitazar. J. Med. Chem. 2003, 46, 1306-1317.
24. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T. J.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. 2001, 98, 13919-13924.
25. Desai, R. C.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Leung, K.; Moller, D. E.; Heck, J. V.; P., S. S. 5-Aryl Thiazolidine-2,4-diones: Discovery of PPAR Dual α/γ Agonists as Antidiabetic Agents. Bioorg. Med. Chem. Lett. 2003, 13, 2795-2798.
26. Desai, R. C.; Gratale, D. F.; Han, W.; Koyama, H.; Metzger, E. J.; Lombardo, V. K.; MacNaul, K. L.; Doebber, T. W.; Berger, J. P.; Leung, K.; Franklin, R.; Moller, D. E.; Heck, J. V.; P., S. S. Aryloxazolidinediones: Identification of Potent Orally Active PPAR Dual α/γ Agonists. Bioorg. Med. Chem. Lett. 2003, 13, 3541-3544.
27. Murakami, K.; Tobe, K.; Ide, T.; Mochizuki, T.; Ohashi, M.; A., Y.; Yazaki, Y.; Kadowaki, T. A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-α (PPAR-α) and PPAR-γ. Effects of PPAR-α Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats. Diabetes. 1998, 47, 1841-1847.
28. Golender, V. E.; Vorpogel, E. R. Computer Assisted-Pharmacophore Identification. 3D-QSAR in Drug Design: Theory, Methods and Application, Kubinyi, H. ESCOM Science Publishers: Netherlands, 1993, 137-154.
29. Golender, V. E. Rosenblit, A. B. Logical and Combinatorial Algorithms in Drug Design; Research Studies Press: Wiley & Sons: 1983; p 352.
30. Cramer, R. D. I.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
31. Klebe, G.; Abraham, U.; Meitzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
32. Robinson, D. D.; Winn, P. J.; Lyne, P. D.; Richards, W. G. Self-organizing molecular field analysis: a tool for structure-activity studies. J. Med. Chem. 1999, 42, 573-583.
33. Silverman, B. D.; Platt, D. E. Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition. J. Med. Chem. 1996, 39, 2129-2140.
34. Gohlke, H.; Klebe, G. DrugScore meets CoMFA: adaptation of fields for molecular comparison (AFMoC) or how to tailor knowledge-based pair-potentials to a particular protein. J. Med. Chem. 2002, 45, 4153-4170.
35. Amin, E. A.; Welsh, W. J. Three-Dimensional Quantitative Structure Activity Relationship (3D-QSAR) Models for a Novel Class of Piperazine-1 (MMP-3) Inhibitors: Applying a "Divide and Conquer" Strategy. J. Med. Chem. 2001, 44, 3849-3855.
36. Aboye, L. T.; Sobhia, M. E.; Bharatam, P. V. 3D-QSAR studies of pyruvate dehydrogenase kinase inhibitors based on a divide and strategy. Biorg. Med. Chem. 2004, 12, 2709-2715.
37. Baskin, I. I.; Tikhonova, I. G.; Palyuin, V. A.; Zefirov, N. S. Selectivity Fields: Comparative Molecular Field Analysis (Co-MFA) of the Glycine/NMDA and AMPA Receptors. J. Med. Chem. 2003, 46, 4063-4069.
38. Berger, J.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M. S.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman R. L.; Smith, R. G.; Moller, D. E. Novel Peroxisome Proliferator-activated Receptor (PPAR)γ and PPARδ Ligands Produce Distinct Biological Effects. J. Biol. Chem. 1999, 274, 6718-6725.
39. SYBYL6.9; Tripos Inc., 1699 S. Hanley Rd., St. Louis, MO 631444 USA.
40. Nolte, R. T.; Wisley, B. G.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.; Rosenfeld, M. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-g. Nature 1998, 395, 137-143.
41. Mulliken, R. S. Electronic Population Analysis on LCAO-MO Molecular Wave Functions I. J. Chem. Phys., 1955, 23, 1833-1846.
42. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A Fast Flexible Docking Methods Using an Incremental Construction... Algorithm. J. Mol. Biol. 1996, 261, 470-489.
43. (a) Clark, R. D.; Strizhev, A.; Leonard J. M.; Blake, J. F.; Mattew, J. B. Consensus scoring for ligand-protein interactions. J. Mol. Graph. Mod., 2002, 20, 281-295.
44. (b) Jones, G.; Willet P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Comput-Aided Mol. Des. 1997, 267, 727-748.
45. (c) Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: a simplified approach. J. Med. Chem. 1999, 42, 791-804.
46. (d) Meng, E. C.; Shoichet, B. K.; Kuntz, I. D. Automated docking with grid-based energy evaluation. J. Comput. Chem. 1992, 13, 505-524.
47. (e) Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions. Part I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput-Aided Mol. Des. 1997, 11, 425-445.